# Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose

> **NCT01300260** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 32 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **BIOLOGICAL:** LY2189265
- **DRUG:** Placebo
- **DRUG:** Insulin
- **DRUG:** Glucose
- **DRUG:** Glucagon

## Key facts

- **NCT ID:** NCT01300260
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01300260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01300260, "Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01300260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*